|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
CHEMOKINES
From the Department of Clinical and Experimental
Medicine, Section of Hematology, University of Verona, Italy.
The tumor necrosis factor receptor family molecule CD30 is
expressed by activated and memory T cells, depending on IL-4
stimulation preferentially in association with Th0- and Th2-type
responses. It mediates pleiotropic effects primarily of the inhibitory
type. Arguing that CD30+ cells have a peculiar
redistribution in disease, it is demonstrated here, in the
Hodgkin-derived L540 cell line (an established model for studying CD30
signaling), that CD30 regulates the prototypic lymphoid chemokine
receptor CXCR4 (CD184), which plays an important role in many organ
systems and is a coreceptor for human immunodeficiency virus-1 entry.
CD30 stimulation with agonistic antibodies in L540 cells led to the
accumulation of CXCR4 mRNA, which reached a plateau after 4 hours and
did not require protein synthesis. It has been reported recently that
CD30 up-regulates the transcription of CCR7 mRNA in YT lymphoma cells.
After mRNA transcription, membrane expression of CXCR4 in L540 cells
increased as early as 12 hours, reached a plateau after 24 hours
(MFI ± SD, 839 ± 122 vs basal 168 ± 28;
P < .01) and was still increased after 5 days,
permitting enhanced sensitivity to the chemotactic activity of
CXCR4-ligand CXCL12 (CI ± SD, 10 ± 1 vs basal 5 ± 2;
P < .01). CD30 cross-linking also induced the release of
CCL5 and CCL3 and the up-regulation of membrane binding capacity for
CCL3 and CCL4 and decreased proliferative activity. This new regulatory
role of CD30 may be relevant for T-cell maturation and effector
responses and for promoting cancer biology.
(Blood. 2002;99:52-60) The tumor necrosis factor receptor (TNFR) family
includes molecules such as TNFR1, TNFR2, CD27, CD30, CD40, CD95, and
OX40, which interact with a corresponding family of TNF-like
cytokines1,2 integrating signals of activation,
proliferation, apoptosis, or differentiation, depending on cell type,
specific receptor expression, coactivation signals, and mobilization of
transduction molecules.1-4 CD30, CD40, OX40, and CD95 at
least have been involved in lymphoid differentiation and effector
functions.5 CD30, originally described as a marker of a
number of lymphoma cells and reactive lymphoblasts,6 is
expressed by activated and memory T cells,6-9 medullary
thymocytes,10,11 B cells, natural killer cells, and some
nonhematologic cells.12 Its expression by T cells is
essentially dependent on activation involving IL-4 and CD28
signaling.9,13 The IL-4 requirement is probably the reason
for the association of CD30 expression with preferential Th0- and
Th2-type immune responses in vitro8 and in
vivo.14-16 Stimulation of CD30 by CD153 (CD30 ligand)
leads to nuclear mobilization of NF- The role of CD30 in HIV-1 infection,15,22 the preferential
association of CD30 with compartmentalized lymphoid subsets during
differentiation11 and effector responses,16
and the evidence that Th1 versus Th2 or naive versus primed T cells are distinguished by specific patterns of CD308 and chemokine
receptor expression25,26 suggest some kind of relationship
between CD30 signals and chemokine function. Recently, Muta et
al27 reported that CD30 signals increased amounts of CCR7
mRNA in the YT lymphoma cell line. Actually, a number of CD30-related
activities seem to integrate cellular functions driven by lymphoid
chemokines, namely their prototypic member CXCL12 (SDF-1) and its
receptor CXCR4 (CD184).28 CXCL12 is expressed constitutively in various cell types28-30 and is an
efficient cell chemoattractant to specific sites.30-32
CXCR4 is expressed by neutrophils, monocytes, naive T lymphocytes,
thymocytes, mature and immature B cells, CD34+
cells,31,32 vascular endothelial cells,33 and
neurologic cells.32 It has been implicated in platelet
formation34 and is a coreceptor for HIV-1
entry.35 CD30 and CD153 are reasonable candidates for
regulating lymphoid chemokines, as are other TNF family-related
molecules, namely lymphotoxin Using the Hodgkin-derived CD4+CD30+ cell line
L540, which is an established in vitro model for studying CD30
signaling,17,18 we found that CD30 cross-linking modifies
CXCR4 expression and function. This activity is potentially relevant to
differentiation, immunity, and cancer because of the extensive roles of
the CXCR4-CXCL12 signaling system from embryogenesis28,38
to lymphoid maturation and function32 to promoting tumor
biology.30
Culture of the cell line L540
Stimulation of the L540 cell line and CD30 ligation
Soluble factors.
L540 cells were treated with one of the following factors: 20 ng/mL
interleukin-2 (IL-2), 40 ng/mL IL-4, 10 ng/mL IL-6, 10 ng/mL IL-10, 10 ng/mL interferon (IFN)- Plastic-anchored agonistic anti-CD30 monoclonal
antibodies.
L540 cells were stimulated in 24-well plates containing immobilized
anti-CD30 agonistic M44 or M67 monoclonal antibodies (mAbs) (kindly
provided by Immunex Research and Development, Seattle, WA) according to
the method described by McDonald et al17 with minor
modifications. Briefly, 24-well polystyrene plates were coated
overnight at 4°C with 10 µg/mL M44, M67, or isotype-matched immunoglobulin (Ig)G1 anti-CD34 mAb (Becton Dickinson, San Jose, CA)
and an isotype-matched nonagonistic anti-CD30 mAb (BerH2; DAKO,
Glostrup, Denmark) in 100 mM carbonate buffer at pH 9.6. Wells were
washed twice with phosphate-buffered saline (PBS) and were blocked with
PBS containing 5 mg/mL bovine serum albumin (BSA) for 90 minutes at
37°C. After further washes, cells were dispensed in wells
(0.15 × 105 cells/well) containing immobilized
antibodies and were cultured up to 72 hours. The optimal stimulation
time (4, 24, 48, or 72 hours) was assessed in preliminary experiments.
There were no substantial differences between M44 and M67 anti-CD30
agonistic mAbs as far as the effects in L540 cells were concerned.
Aliquots of cells were also pretreated with 20 µg/mL cycloheximide
(CHX) before stimulation with PMA-ion or M67 mAb for 4 hours.
Northern blot and reverse transcription-polymerase chain
reaction
Northern blot analysis.
Northern blot analysis (10 µg/lane) was performed as previously
described.40 Filters were hybridized with
32P-labeled complementary DNA (cDNA) probes to CCR5 and
CXCR4 obtained as specified above and with a 32P-labeled
plasmid containing a cDNA probe to Reverse transcription-polymerase chain reaction. For RT-PCR, 4 µg RNA was reverse-transcribed as previously described41,42 and was cDNA amplified using the following primers: (1) CXCR4 sense 5'-AGAACCAGCGGTTACCATGGA-3' and antisense 5'-GAGTGTGACAGCTTGGAGATG-3' (702 bp); (2) CCR1 sense 5'-GAAACTCCAAACACCACAGAG-3' and antisense 5'-CAGCTTCCACTCTCGTAGGCTT-3' (588 bp); (3) CCR3 sense 5'-TCCTT CTCTCTTCCTATCAATC-3' and antisense 5'-GGCAATTTTCTGCATCTG-3' (313 bp); (4) CCR5 sense 5'-CGCATCAAGTGTCAAGTCCAATC-3' and antisense 5'-TG TAAACTGAGCTTGCTCGCT-3' (1014 bp); (5) Vimentin sense 5'-GCTCAGATTCAGGAACAGCAT-3' and antisense 5'-TAAGGGCATCCACTTCACAGG-3' (266 bp). cDNAs were denatured for 5 minutes at 94°C before 35 runs at 58, 52, 57, and 60°C for 40, 30, 40, and 40 seconds, respectively (annealing) and at 72°C for 50 seconds (elongation) followed by 5 minutes at 72°C in a thermal cycler (GeneAmp PCR System 2400; PE Biosystems, Foster City, CA) using 1.25 U Taq polymerase (PE Biosystems) in 50 µL. PCR products were separated by electrophoresis on 1.5% agarose gel. CXCR4 and CCR5 cDNAs amplified from the L540 cell line using the primers specified above were analyzed for the BamHI and EcoRI (Life Technologies) restriction sites, respectively (which gave the expected CXCR4 fragments of 498 and 204 bp and the expected CCR5 fragments of 780 and 234 bp). They were sequenced (Sequenase 2.0 sequencing kit; USB, Cleveland, OH) as plasmid inserts (TA cloning kit; Invitrogen, San Diego, CA) from which the CXCR4 and CCR5 probes were generated for Northern blot analysis. Electrophoretic mobility shift assay After 20 to 60 minutes of culture in the presence or absence of M44, M67, or PMA-ion as reported above, nuclear extracts were prepared as previously described.17 Briefly, cells were harvested and centrifuged at 2000g for 2 minutes. The pellets were washed and resuspended in 100 µL ice-cold lysis buffer (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 1.5 mM MgCl2, 0.5 mM EDTA, 0.5 mM EGTA) containing 0.15% NP40 and antiproteases (1 mM phenylmethylsulfonyl fluoride and 10 µg/mL each of aprotinin, leupeptin, and pepstatin A). Cells were incubated on ice for 10 minutes, vortexed briefly, and centrifuged at 1000g for 10 minutes at 4°C. Nuclear pellets were washed twice in lysis buffer containing the antiproteases and were incubated for 15 minutes on ice in nuclear extraction buffer (20 mM HEPES, pH 7.9, 420 mM NaCl, 1.5 mM MgCl2, 0.5 mM EDTA, 0.5 mM dithiothreitol, 20% vol/vol glycerol) containing the antiprotease cocktail. Extracted nuclear fractions were then centrifuged at 16 000g for 15 minutes at 4°C, and the resultant supernatants were made into aliquots and were stored at 70°C before use. Binding reactions were performed in
20 µL binding buffer (20 mM Tris-HCl, pH 7.5, 80 mM KCl, 1 mM
dithiothreitol, 0.1% NP40, 6% glycerol) supplemented with 20 µg
acetylated BSA and 1 µg poly(dI).poly(dC). The following
( -32P) adenosine triphosphate (Amersham International,
Little Chalfont, United Kingdom) end-labeled, double-strand
oligonucleotides were used as probes: (1)
5'-GATCAGGGACTTTCCGCTGGGGACTTTCC-3', containing tandem repeats of the
consensus NF- B binding site identical to those found in the HIV
promoter; (2) 5'-GATCGAT CGGGGCGGGGCGATC-3', containing the consensus
Sp1-binding site; (3) 5'-CAGCGGCGCATGCGCCGCGCTC-3', containing the
binding sequence for NRF-1; (4) 5'-CGCTTGATGACTCAGCCGGAA-3', containing
the DNA binding site for the AP-1/c-jun homodimer complex. Samples were separated on 5% native polyacrylamide gels and were visualized by autoradiography.
RNase protection assay Detection of chemokine message expression was performed with an RNase protection analysis system (RiboQuant; BD PharMingen) on cells in basal conditions or treated as reported above. A multiprobe template set (hCK-5) was used for the in vitro transcription reaction using T7 polymerase to direct the synthesis of high-specific-activity 32P-labeled antisense RNAs that hybridize with human RNAs encoding XCL1 (lymphotactin ), CCL5 (RANTES), CXCL10 (IP-10), CCL4
(MIP-1 ), CCL3 (MIP-1), CCL2 (MCP-1), CXCL8 (IL-8), CCL1 (I-309),
and 2 housekeeping control gene products, L32 and GAPDH. After
hybridization, samples were treated with RNase A and proteinase K, and
the protected probes were resolved on a 5% acrylamide-urea gel and
were quantified by autoradiography.
Flow cytometry analysis Cells in basal conditions or stimulated for 72 hours as reported above were harvested, washed twice with PBS, and stained (1 × 106) for 1 hour at 4°C with anti-CD30-fluorescein isothiocyanate (FITC; DAKO), anti-CXCR4-phycoerythrin (PE) (12G5; BD PharMingen), anti-CCR5-PE (BD PharMingen) mAbs, and isotype-fluorochrome-matched controls, as previously described.43 In selected experiments, CXCR4 internalization in L540 cells was evaluated according to the method described by Signoret et al44 adapted to flow cytometry. Cells were also tested for the binding of biotinylated CCL3 and CCL4 using commercially available kits (R&D Systems, Minneapolis, MN). The manufacturer's protocols were followed with minor modifications. Briefly, 1 × 106 cells were washed twice in PBS, incubated for 90 minutes at 4°C with biotinylated cytokine, added to avidin-FITC reagent for 30 minutes, and washed twice with the buffer supplied. Controls for specificity of binding were performed using neutralizing concentrations of nonbiotinylated CCL3 and CCL4. Flow cytometry analysis was performed on a FACScan (Becton Dickinson, Mountain View, CA) using the CELLQuest analysis program.Detection of soluble molecules in culture supernatants Soluble CD30, CCL3, CCL4, and CCL5 proteins in culture cell-free SN derived from cells in basal conditions or stimulated for 72 hours with mAb M67 or M44 or with PMA-ion as reported above were measured using commercially available ELISA kits (DAKO and R&D Systems, respectively). Briefly, 100 to 200 µL SN alone (CCL3, CCL4, CCL5) or SN added to enzyme-conjugated antibody (CD30) were incubated in duplicate for 2 hours at room temperature in 96-well microplates coated with specific antibodies. After washing, the samples were directly treated with substrate solution (CD30) or were added to enzyme-conjugated antibodies for 2 hours, washed, and treated with substrate solution (CCL3, CCL4, CCL5). The enzymatic reactions were stopped and read within 30 minutes at 450 nm on an AutoReader III (Ortho Diagnostic Systems, Raritan, NJ).Chemotaxis assay Chemotaxis assay was performed following a modification of a published procedure.45 Cells in basal conditions or stimulated for 72 hours with mAb M67 or M44 or PMA-ion with, as reported above, were washed twice in chemotaxis buffer (RPMI 1640, 20 mM HEPES, 0.4% BSA), resuspended at a density of 5 × 106/mL, and incubated for 1 hour in the presence or absence of 50 µg/mL of neutralizing anti-CXCR4 (12G5) or isotype-matched control mAbs (BD PharMingen). Aliquots of 100 µL cell suspensions were seeded in the upper chamber of a 24-well, 8-µm pore polycarbonate Transwell culture insert (Costar, Cambridge, MA) and were incubated for 90 minutes at 37°C. The lower chamber was filled with 600 µL chemotaxis buffer alone or containing 200 ng/mL CXCL12 (SDF-1; BD PharMingen). In selected experiments, the inhibitory
effect of CXCL12 in the upper chamber on migration of L540 cells was also evaluated according to Wang et al.34 Cells that
migrated into the lower chamber through the membrane pores were
resuspended and counted with a FACScan (Becton Dickinson) for 20 seconds at a 60 µL/min flow rate. Results were expressed as
percentage of migrated cells or chemotactic index (CI = cells
migrating to CXCL12/cells migrating to medium).
Proliferation of L540 cells The L540 cell proliferation in basal conditions and after stimulation with IL-2, M67 or M44 mAb, or PMA-ion, as reported above, was measured after 72-hour culture as follows.Incorporation of 5-bromo-2'-deoxyuridine. Cells were added with 10 µM BrdU (Sigma), incubated for 1 hour at 37°C, washed twice with PBS, and fixed in 70% ethanol. Cell suspensions were centrifuged and incubated with 3 N HCl for 20 minutes. After neutralizing with 0.1 M Na2B4O7, cells were resuspended in 100 µL PBS containing 0.5% BSA and were stained with 10 µL anti-BrdU-FITC or isotype-matched control mAbs (Becton Dickinson) for 30 minutes at room temperature, washed twice in PBS, and analyzed with a FACScan (Becton Dickinson). Results were expressed as a percentage of BrdU-positive cells of the total number of acquired cells. 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. MTT assay was performed as previously described.46 Cells were added with 10 µL 5 mg/mL MTT solution, incubated at 37°C for 4 hours, lysed with 0.04 N HCl in isopropanol, and read (wavelengths: test 570, reference 630 nm) on an AutoReader III (Ortho Diagnostic Systems). Results were expressed as percentage proliferation of stimulated versus unstimulated cells. Statistical analysis Student t test, Mann-Whitney U test, and Kruskall-Wallis analysis of variance by ranks were used. Differences were considered statistically significant when P < .05.
Expression pattern in resting L540 cells The pattern of relevant molecules in resting L540 cells is listed in Table 1. L540 cells were CD3 CD4+ (MFI ± SD, 900 ± 30) and
strongly CD30+ (1370 ± 252). When we examined the
presence of a number of CC and CCR mRNAs or molecules using RPA,
RT-PCR, flow cytometry, and ELISA, we found that L540 cells transcribed
CCR1, CCR2, CCR3, and CXCR4 mRNAs, released CCL3 CCL4, and CCL5, and
had clear membrane expression of CXCR4 at flow cytometry (168 ± 28).
Specific binding capacities for fluorochrome-labeled CCL3 and CCL4 were
also expressed on resting L540 cell membrane (70 ± 15 and
439 ± 47, respectively).
CD30-triggering-induced increase in CXCR4 mRNA To investigate whether CXCR4 mRNA was transcribed, L540 cells were initially cultured for 4 hours in the presence or absence of PMA-ion, 10 µg/mL plastic-bound anti-CD30 agonistic mAb M67 or M44, and isotype-matched anti-CD34 mAb and anti-CD30 nonagonistic, indifferent BerH2 mAb as controls. Total RNA was then processed for Northern blot analysis. Figure 1 shows that resting L540 cells produced small amounts of CXCR4 mRNA. By contrast, PMA-ion- and CD30-stimulated (M67) L540 cells showed a considerable accumulation of CXCR4 transcripts of the expected 1.7-kb size, with a pattern matching that observed in other cell types.33 In addition, transcripts corresponding to a larger 4.0-kb mRNA present in all conditions were not subject to regulation by anti-CD30 agonistic mAbs or PMA-ion. These transcripts are likely to correspond to the unspliced isoform of CXCR4, termed CXCR4-Lo.47 Consistent with the genuine ability of L540 cells to accumulate CXCR4 mRNA in response to CD30 stimulation were additional experiments in which, by contrast, a wide panel of cytokines (Table 2) did not influence the levels of CXCR4 mRNA.
CXCR4 mRNA accumulation pattern Kinetic experiments revealed that maximal expression of CXCR4 1.7-kb mRNA occurred after 4 hours of stimulation with anti-CD30 mAb (Figure 1) and that an increase of CXCR4 density on the membrane of the L540 cells followed (see below). A similar accumulation of CXCR4 1.7-kb mRNA was detectable after stimulation with PMA-ion, but was associated with a reduced membrane expression of the CXCR4 molecule, in line with previous reports.33,44 After 24 hours, increased levels of CXCR4 mRNA transcripts were still detectable in cells treated with PMA-ion and especially with anti-CD30 mAb (Figure 1). We also examined whether de novo protein synthesis was necessary for the CD30-driven induction of CXCR4 mRNA in L540 cells. As shown in Figure 1, the inhibitor of protein synthesis CHX not only did not inhibit, but actually superinduced, the anti-CD30-dependent accumulation of 1.7- and 4.0-kb mRNA for CXCR4.NF- B is substantially similar in L540 cells,
peripheral T lymphocytes, and T-cell clones derived from peripheral T
cells.17 After stimulation of CD30 on L540 cells through
plastic-bound agonistic mAb M44 or M67, NF-B nuclear translocation
followed as expected (Figure 2),
involving p50 and p65 NF-B complexes, as previously
shown.17 The effects on NF-B complexes induced by
stimulation with M67, M44, or PMA-ion were similar in the current experiments, as previously reported.17
Specific inducers for the CXCR4 promoter Because NF-B-related binding sites are not present on the
CXCR4 promoter,35 we conducted shift experiments to study
the following molecules known to be involved in CXCR4 gene
regulation35,48,49: NRF-1, a specific transcription factor
for the CXCR4 promoter, usually involved in the constitutive expression
of the CXCR4 gene35,49; Sp1 complexes targeted
to GC boxes on the CXCR4 promoter35,48; and AP-1
(c-jun) factors, which recognize a specific motif on the
CXCR4 promoter35,49 and are putatively mobilized by
CD30 signaling through modulation of TRAF-2.3 NRF-1, SP1,
and AP-1 transcription factors were detectable in L540 cell nuclei in
basal conditions (Figure 2). Their amounts, however, proved to be
unaffected after CD30 stimulation. By contrast, PMA-ion induced
nuclear mobilization of AP-1 (Figure 2), accounting for the
PMA-dependent CXCR4 mRNA up-regulation.
CD30 triggering-induced increase in CXCR4 membrane expression CD30 stimulation was associated with a clear-cut increase in CXCR4 membrane expression as early as 12 hours, which reached a plateau after 24 hours (MFI ± SD, 839 ± 122 versus basal condition 168 ± 28; P < .01) (Figure 3) and was still present after 5 days. After PMA-ion stimulation, despite increased levels of CXCR4 mRNA similar to those induced after CD30 stimulation, a clear-cut reduction of the membrane density of CXCR4 was detectable33,44 (Table 2, Figure 3). Consistent with a reduction from internalization33,44 were 3 additional experiments in which PMA-ion stimulation induced cytoplasmic translocation of fluorescent mAbs previously bound to membrane CXCR4. The cytoplasmic translocation of the CXCR4-fluorescent mAb complex was abolished by 1 M sucrose-containing medium, which inhibits clathrin-coated vesicle formation50 (data not shown). The membrane expression of CXCR4 was variously affected when L540 cells were stimulated with a panel of other factors known to regulate the surface expression of a number of receptors (Table 2), and we never observed any spontaneous increase in CXCR4 expression as a result of the culture conditions. Thus, the up-regulation of CXCR4 was a genuine, specific effect of CD30 ligation.
Variable regulation of CXCR4 membrane expression by interleukins For comparative purposes, we examined the effect of IFN-, IL-4,
IL-6, and IL-10 on the membrane expression of CXCR4 in L540 cells. The
effect of pretreatment with CHX of L540 cells stimulated with anti-CD30
agonistic mAbs was also evaluated. According to the results reported in
Table 2, the membrane expression of CXCR4 was unaffected after
stimulation with GM-CSF, IL-2, and CHX alone. A decrease in CXCR4
expression was induced by stimulation with IFN-, IL-4, and IL-6.
Stimulation with IL-10 led to up-regulation of the CXCR4 molecule on
the membrane of L540 cells. IL-10 was a weaker inducer of CXCR4 than
M44 or M67 alone, whereas M44 and M67+CHX were the strongest inducers
of CXCR4 (Table 2).
CXCL12-dependent chemotaxis after CD30-induced increase in CXCR4 Cells exposing CXCR4 on their membranes are usually sensitive to chemotactic activity induced by CXCL12. When tested in basal conditions, CXCR4+ L540 cells were responsive to CXCL12-dependent chemotactic signals with a CI of 5 ± 2, compared to a CI of 10 ± 1 when stimulated with anti-CD30 agonistic mAbs (P = .003; Figure 4). CXCL12 concentrations in the upper chamber inhibited the migration of L540 cells34 (data not shown). This migration pattern was abolished in experiments involving preincubation of L540 cells with neutralizing anti-CXCR4 mAbs, whereas indifferent isotype-matched mAbs were ineffective (Figure 4). L540 cells stimulated with PMA-ion were poorly sensitive to CXCL12-dependent chemotaxis (Figure 4).
CD30 shedding after CD30 ligation and PMA stimulation Stimulation of CD30 induced a decrease in the membrane density of the CD30 molecule itself (Figure 3), paralleled by an increase in its concentration in culture SN (Figure 5). Forty-eight-hour stimulation of L540 cells with M67 reduced the CD30 membrane MFI ± SD from 1370 ± 252 to 600 ± 138 (P < .01). A similar trend was observed using PMA-ion as the stimulator, which induced a decrease to 854 ± 119 (P < .01). These effects lasted up to 96 hours after stimulus delivery. The concentration of CD30 in 48-hour culture SN was 24 ± 9 U/mL for unstimulated L540 cells. It was 64 ± 10 (P < .01), 50 ± 8 (P < .01), and 95 ± 22 (P < .01) U/mL after stimulation with M67, PMA-ion, and M67+PMA-ion, respectively. By contrast, the nonagonistic anti-CD30 mAb BerH2 induced no statistically significant variations compared with controls, either in CD30 membrane MFI (1343 ± 230) or in culture SN concentration (20 ± 7 U/mL).
Release of CCL3, CCL4, and CCL5 after CD30 ligation We investigated whether M67-treated L540 cells released CCL3, CCL4, and CCL5 proteins into the culture SN. To this end, we used specific commercial ELISAs with threshold sensitivities of 6, 4, and 8 pg/mL (pM) for CCL3, CCL4, and CCL5, respectively. As shown in Figure 5, detectable yields of CCL3 and CCL5 were measured in SN harvested from resting L540 cells (6 ± 2 and 270 ± 38 pg/mL, respectively), which increased to 710 ± 50, 2805 ± 235, 600 ± 136, and 1775 ± 278 pg/mL after treatment with PMA-ion and M67+PMA-ion, respectively (P < .01). M67 alone had no effect on the release of CCL3, whereas it induced a CCL5 SN concentration of 780 ± 165 (P < .01). The basal release of CCL4 (10 ± 3 pg/mL) was not substantially affected by the stimuli reported above.CCL3 and CCL4 binding to membrane receptors after CD30 ligation The ability of biotinylated CCL3 and CCL4 to specifically bind to receptors on the L540 cell membrane was also modified by CD30 triggering. The basal binding for these chemokines gave an MFI ± SD of 70 ± 15.3 and 439 ± 47 for CCL3 and CCL4, respectively. After stimulation with M67 alone, the binding of both chemokines was greatly increased (210 ± 12, P = .006, and 818 ± 89, P = .019, respectively). PMA-ion stimulation did not affect the binding capacity for CCL3 (74 ± 12), and it induced a modest increase in that for CCL4 (535 ± 56; P = .029).L540 cell growth modulation after CD30 ligation and IL-2 stimulation CD30 stimulation has pleiotropic effects on lymphoma cell lines. L540 cells have been reported to proliferate in response to stimulation by CD30.18 In our experiments, this was not the case. As shown in Table 3, agonistic anti-CD30 mAbs reduced the proliferative activity of L540 cells by at least 30%, as evaluated by BrdU incorporation analysis. IL-2, which we evaluated for comparative purposes, induced a similar down-regulation of L540 cell proliferative activity, as previously reported.51
The current study defines a new mechanism, the induction of CXCR4, whereby CD30 regulates the cellular functions involved in directing the specific homing of activated cells in specific microenvironments. In the CD30+ cell line L540, previously exploited to
dissect CD30-mediated activities,17,18 CD30 cross-linking
with agonistic anti-CD30 mAb M67 or M44 led to 3 occurrences:
up-regulation of the expression of CXCR4 (Figure 3), after accumulation
of its mRNA (Figure 1), permitting increased cell sensitivity to the specific chemotactic activity of CXCL12 (Figure 4); release of CCL5 and
CCL3 (Figure 5) associated with up-regulation of membrane-binding capacity for CCL3 and CCL4 (Figure 6);
and decreased proliferative activity (Table 3). The up-regulation of
CXCR4 mRNA and membrane molecules induced by CD30 triggering in L540
cells was genuine and specific, as demonstrated by the different
effects induced by other factors and by the selective response to
CXCL12. Among the other factors tested (Table 2), only IL-10
up-regulated CXCR4, though to a lesser extent than CD30. The classic
stimulator, PMA-ion, induced an increase in CXCR4 mRNA (Figure 1), but
the surface density of CXCR4 decreased (Figure 3) primarily because of
internalization.33,44 Moreover, while this work was in
progress, Muta et al27 reported the surprising, unexpected
finding that CD30 signals led to a 5.8-fold increase in CCR7 mRNA in YT
lymphoma cells, arguing that, through CCR7, CD30 signals integrate
lymphocyte trafficking, proliferation, and apoptosis.
Thus, engagement of CD30 by CD153, which is associated
preferentially with Th2-type effector responses,19
regulates CXCR4 and CCR727 expression and delivers
inhibitory signals,20,27 leading to impaired clonal
expansion of peripheral T cells,21 sensitizing to
TNFR1-dependent apoptosis,3 and counteracting IgG and IgA
production.52 This cellular-level regulation seems to have
a counterpart in a number of conditions, sharing the tendency to
selective compartmentalization of low-proliferating CD30+
cells, which deliver locally anti-inflammatory cytokines, such as IL-4
and IL-10, whenever tested for16 and which generate a
molecular milieu characterized by features of immune
suppression.16,20 These conditions include autoimmune
diabetes in mouse models,21 rheumatoid
arthritis,16 Omenn syndrome,14 a severe
immunodeficiency characterized by features reminiscent of a Th2-type
response in which large proportions of tissue-infiltrating
CD30+ cells are present, measles53 in which
CD30+ cell expansion is related to the impaired mitogenic
capability of T lymphocytes, inadequate Th1-type responses, and cell
recruitment to lymph nodes and skin. A faster progression to acquired
immunodeficiency syndrome reported for asymptomatic HIV-1+
patients with immune responses characterized by higher CD30
expression22,23 may be explained by the combined effect of
NF- CXCR4-CXCL12 and CCR7-CCL21 systems are involved in the
migration of hematopoietic and nonhematopoietic cells in
vivo.28,29,31,38 CXCR4-CXCL12 mediates chemotaxis for
monocytes, neutrophils, and T cells, but it is also involved in early
activation events and in the production of IL-2, IFN- CD30+ cancers either of hematologic6 or nonhematologic lineage12 have distinctive clinical features and localize to CXCL12-CCL21-rich tissues, including the lymph nodes, spleen, liver, bone marrow, lung, and brain,4,30,61,62 with a diffusion pattern that may be conditioned by CD30-dependent regulation of CXCR4 and CCR7.30 The thymic microenvironment is rich in CXCL12+CD153+ epithelial cells and in CD30+CXCR4+ T cells. Overexpression of CD30 has been related to negative selection of double-positive cells in thymic medulla10 and the interaction of CD30 with CD153 to the constitution of Hassal corpuscles.11 Although there is no appreciable change in CXCL12 responsiveness from the cortex to the medulla,58 a less intense medullary expression of CXCR4 has been reported63 that may reflect the reduced density of lymphocytes there,58,63 as a result of apoptotic events favored by CD30 stimulation in the medullary context.10 CCR7 is preferentially expressed in transitional cells57 and medullary CD30+ cells.11,58 Thus, synergistic effects of CXCL12 and CCL2130 may be driven by CD30 stimulation during thymic differentiation. One point of interest is whether the CD30-dependent increase in
CXCR4 mRNA was transcriptionally regulated. It reached a plateau after
4 hours and was independent of protein synthesis. Elements regulating
the transcription unit of the human CXCR4 gene include NRF-1, Sp1, and AP-1, but no NF- In conclusion, our data demonstrate that CD30 participates in the regulation of molecules that permit selective migration to specific sites. This role of CD30 may be relevant during lymphoid differentiation or antigen-driven effector responses or in promoting cancer biology, and it may provide a unifying basis for explaining the significance of CD30 in physiology and pathology.
This article is dedicated to the memory of the hematologist Professor Giuseppe Perona, who passed away on April 30, 2001. He was a radical humanitarian, a source of wisdom, and a man of ideas, gifted with uncommon intelligence, culture, and scientific insight. The authors are indebted to him for their knowledge and sense of purpose.
Submitted June 5, 2001; accepted August 30, 2001.
Supported by grants from ISS-National AIDS Research Program, MURST (60% funds and cofinanziamento MURST-Università 40%), Associazione Italiana per la Ricerca sul Cancro (Milan), and Progetto Sanità, Fondazione Cassa di Risparmio VR-VI-BL-AN (Verona).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Fabrizio Vinante, Section of Hematology, Policlinico GB Rossi, 37134 Verona, Italy; e-mail: fabrizio.vinante{at}univr.it.
1. Smith CA, Farrah T, Goodwin RG. The TNF-receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 1994;76:959-962[CrossRef][Medline] [Order article via Infotrieve]. 2. Smith CA, Gruss HJ, Davis T, et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell. 1993;73:1349-1360[CrossRef][Medline] [Order article via Infotrieve].
3.
Duckett CS, Thompson CB.
CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival.
Genes Dev.
1997;11:2810-2821
4.
Mir SS, Richter BW, Duckett CS.
Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells.
Blood.
2000;96:4307-4312 5. Gruss HJ, Duyster J, Herrmann F. Structural and biological features of the TNF receptor and TNF ligand superfamilies: interactive signals in the pathobiology of Hodgkin's disease. Ann Oncol. 1996;7(suppl 4):19-26.
6.
Stein H, Mason DY, Gerdes J, et al.
The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells.
Blood.
1985;66:848-858 7. Ellis TM, Simms PE, Slivnick DJ, Jack H-M, Fisher RI. CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J Immunol. 1993;151:2380-2389[Abstract]. 8. Del Prete G, De Carli M, Almerigogna F, et al. Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. FASEB J. 1995;9:81-86[Abstract]. 9. Nakamura T, Lee RK, Nam SY, et al. Reciprocal regulation of CD30 expression on CD4+ T cells by IL-4 and IFN-gamma. J Immunol. 1997;158:2090-2098[Abstract]. 10. Amakawa R, Hakem A, Kundig TM, et al. Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell. 1996;84:551-562[CrossRef][Medline] [Order article via Infotrieve].
11.
Romagnani P, Annunziato F, Manetti R, et al.
High CD30 ligand expression by epithelial cells and Hassal's corpuscles in the medulla of human thymus.
Blood.
1998;91:3323-3332 12. Durkop H, Foss HD, Eitelbach F, et al. Expression of the CD30 antigen in non-lymphoid tissues and cells. J Pathol. 2000;190:613-618[CrossRef][Medline] [Order article via Infotrieve].
13.
Gilfillan MC, Noel PJ, Podack ER, Reiner SL, Thompson CB.
Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines.
J Immunol.
1998;160:2180-2187 14. Chilosi M, Facchetti F, Notarangelo LD, et al. CD30 cell expression and abnormal soluble CD30 serum accumulation in Omenn's syndrome: evidence for a T helper 2-mediated condition. Eur J Immunol. 1996;26:329-334[Medline] [Order article via Infotrieve]. 15. Del Prete G, Maggi E, Pizzolo G, Romagnani S. CD30, Th2 cytokines and HIV infection: a complex and fascinating link. Immunol Today. 1995;16:76-80[CrossRef][Medline] [Order article via Infotrieve]. 16. Gerli R, Lunardi C, Vinante F, Bistoni O, Pizzolo G, Pitzalis C. Role of CD30+ T cells in rheumatoid arthritis: a counter-regulatory paradigm for the Th1-driven diseases. Trends Immunol. 2001;22:72-77[CrossRef][Medline] [Order article via Infotrieve]. 17. McDonald PP, Cassatella MA, Bald A, et al. CD30 ligation induces nuclear factor-kappa B activation in human T cell lines. Eur J Immunol. 1995;25:2870-2876[Medline] [Order article via Infotrieve].
18.
Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG.
Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines.
Blood.
1994;83:2045-2056
19.
Del Prete G, De Carli M, D'Elios MM, et al.
CD30-mediated signaling promotes the development of human T helper type 2-like T cells.
J Exp Med.
1995;182:1655-1661 20. Cerutti A, Kim EC, Shah S, et al. Dysregulation of CD30+ T cells by leukemia impairs isotype switching in normal B cells. Nat Immunol. 2001;2:150-156[CrossRef][Medline] [Order article via Infotrieve]. 21. Kurts C, Carbone FR, Krummel MF, Koch KM, Miller JFAP, Heath WR. Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature. 1999;398:341-344[CrossRef][Medline] [Order article via Infotrieve]. 22. Pizzolo G, Vinante F, Morosato L, et al. High serum levels of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS. AIDS. 1994;8:741-745[Medline] [Order article via Infotrieve]. 23. Rizzardi GP, Tambussi G, Barcellini W, et al. Soluble CD30, tumour necrosis factor (TNF)-alpha, and TNF receptors in primary HIV-1 infection: relationship with HIV-1, RNA, clinical outcome and early antiviral therapy. J Biol Regul Homeost Agents. 1997;11:43-49[Medline] [Order article via Infotrieve]. 24. Biswas P, Smith CA, Goletti D, Hardy EC, Jackson RW, Fauci AS. Cross-linking of CD30 induces HIV expression in chronically infected T cells. Immunity. 1995;2:587-596[CrossRef][Medline] [Order article via Infotrieve].
25.
Sallusto F, Lenig D, Mackay CR, Lanzavecchia A.
Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes.
J Exp Med.
1998;187:875-883 26. Mackay CR. Follicular homing T helper (Th) cells and the Th1/Th2 paradigm. J Exp Med. 2000;192:F31-F34[CrossRef][Medline] [Order article via Infotrieve].
27.
Muta H, Boise LH, Fang L, Podack ER.
CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis.
J Immunol.
2000;165:5105-5111 28. Mackay CR. Chemokines: immunology's high impact factors. Nat Immunol. 2001;2:95-101[CrossRef][Medline] [Order article via Infotrieve].
29.
Nanki T, Lipsky PE.
Cutting edge: stromal cell-derived factor-1 is a costimulator for CD4+ T cell activation.
J Immunol.
2000;164:5010-5014 30. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50-56[CrossRef][Medline] [Order article via Infotrieve].
31.
Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA.
A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1).
J Exp Med.
1996;184:1101-1109
32.
Murphy PHM, Baggiolini M, Charo IF, et al.
International Union of Pharmacology, XXII: nomenclature for chemokine receptors.
Pharmacol Rev.
2000;52:145-176
33.
Gupta SK, Pillarisetti K, Lysko PG.
Modulation of CXCR4 expression and SDF-1
34.
Wang J-F, Liu Z-Y, Groopman JE.
The 35. Moriuchi M, Moriuchi H, Turner W, Fauci AS. Cloning and analysis of the promoter region of CXCR4, a coreceptor for HIV-1 entry. J Immunol. 1997;159:4322-4329[Abstract].
36.
Ngo VN, Korner H, Gunn MD, et al.
Lymphotoxin alpha/beta and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen.
J Exp Med.
1999;189:403-412
37.
Moir S, Lapointe R, Malaspina A, et al.
CD40-mediated induction of CD4 and CXCR4 on B lymphocytes correlates with restricted susceptibility to human immunodeficiency virus type 1 infection: potential role of B lymphocytes as a viral reservoir.
J Virol.
1999;73:7972-7980 38. McGrath KE, Koniski AD, Maltby KM, McGann JK, Palis J. Embryonic expression and function of the chemokine SDF-1 and its receptor, CXCR4. Dev Biol. 1999;213:442-456[CrossRef][Medline] [Order article via Infotrieve]. 39. Diehl V, Pfreundschuh M, Fonatsch C, et al. Phenotypic and genotypic analysis of Hodgkin's disease derived cell lines: histopathological and clinical implications. Cancer Surv. 1985;4:399-419[Medline] [Order article via Infotrieve]. 40. Vinante F, Rigo A, Vincenzi C, et al. IL-8 mRNA expression and IL-8 production by acute myeloid leukemia cells. Leukemia. 1993;7:1552-1556[Medline] [Order article via Infotrieve]. 41. Vinante F, Rigo A, Tecchio C, et al. Serum levels of p55 and p75 soluble TNF receptors in adult acute leukaemia at diagnosis: correlation with clinical and biological features and outcome. Br J Haematol. 1998;102:1025-1034[CrossRef][Medline] [Order article via Infotrieve].
42.
Vinante F, Marchi M, Rigo A, Scapini P, Pizzolo G, Cassatella MA.
Granulocyte-macrophage colony-stimulating factor induces expression of heparin-binding epidermal growth factor-like growth factor/diphtheria toxin receptor and sensitivity to diphtheria toxin in human neutrophils.
Blood.
1999;94:3169-3177 43. Vinante F, Pizzolo G, Rigo A, et al. The CD4 molecule belongs to the phenotypic repertoire of most cases of acute myeloid leukemia. Leukemia. 1992;6:1257-1262[Medline] [Order article via Infotrieve].
44.
Signoret N, Oldridge J, Pelchen-Matthews A, et al.
Phorbol esters and SDF-1 induce rapid endocytosis and down modulation of the chemokine receptor CXCR4.
J Cell Biol.
1997;139:651-664 45. Taub DD, Key ML, Clark D, Turcovski-Corrales SM. Chemotaxis of T lymphocytes on extracellular matrix proteins: analysis of the in vitro method to quantitate chemotaxis of human T cells. J Immunol Methods. 1995;184:187-198[CrossRef][Medline] [Order article via Infotrieve].
46.
Vinante F, Rigo A, Papini E, Cassatella MA, Pizzolo G.
Heparin-binding epidermal growth factor-like growth factor/diphtheria toxin receptor expression by acute myeloid leukemia cells.
Blood.
1999;93:1715-1723
47.
Gupta SK, Pillarisetti K.
Cutting edge: CXCR4-Lo: molecular cloning and functional expression of a novel human CXCR4 splice variant.
J Immunol.
1999;163:2368-2372 48. Caruz A, Samsom M, Alonso JM, et al. Genomic organization and promoter characterization of human CXCR4 gene. FEBS Lett. 1998;426:271-278[CrossRef][Medline] [Order article via Infotrieve].
49.
Wegner SA, Ehrenberg PK, Chang G, Dayhoff DE, Sleeker AL, Michael NL.
Genomic organization and functional characterization of the chemokine receptor CXCR4, a major entry co-receptor for human immunodeficiency virus type 1.
J Biol Chem.
1998;273:4754-4760 50. Pelchen-Matthews A, Signoret N, Klasse PJ, Fraile-Ramos A, Marsh M. Chemokine receptor trafficking and viral replication. Immunol Rev. 1999;168:33-49[CrossRef][Medline] [Order article via Infotrieve]. 51. Tesch H, Herrmann T, Abts H, Diamantstein T, Diehl V. High affinity IL-2 receptors on a Hodgkin's derived cell line. Leuk Res. 1990;14:953-960[CrossRef][Medline] [Order article via Infotrieve].
52.
Cerutti A, Schaffer A, Goodwin RG, et al.
Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+ IgM+ B cells.
J Immunol.
2000;165:786-794
53.
Vinante F, Krampera M, Morosato L, Rigo A, Romagnani S, Pizzolo G.
Peripheral T lymphocyte cytokine profile (IFN-
54.
Stein JV, Rot A, Luo Y, et al.
The CC chemokine thymus-derived chemotactic agent 4 (TCA-4, secondary lymphoid tissue chemokine, 6Ckine, exodus-2) triggers lymphocyte function-associated antigen 1-mediated arrest of rolling T lymphocytes in peripheral lymph node high endothelial venules.
J Exp Med.
2000;191:61-76
55.
Yoshida R, Imai T, Hieshima K, et al.
Molecular cloning of a novel human CC chemokine EBI1-ligand chemokine that is a specific functional ligand for EBI1, CCR7.
J Biol Chem.
1997;272:13803-13809 56. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708-712[CrossRef][Medline] [Order article via Infotrieve].
57.
Randolph DA, Huang G, Carruthers CJ, Bromley LE, Chaplin DD.
The role of CCR7 in TH1 and TH2 cell localization and delivery of B cell help in vivo.
Science.
1999;286:2159-2162
58.
Campbell JJ, Pan J, Butcher EC.
Cutting edge: developmental switches in chemokine responses during T cell maturation.
J Immunol.
1999;163:2353-2357 59. Ma Q, Jones D, Springer TA. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity. 1999;10:463-471[CrossRef][Medline] [Order article via Infotrieve].
60.
Nanki T, Hayashida K, El-Gabalawy HS, et al.
Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium.
J Immunol.
2000;165:6590-6598
61.
Falini B, Pileri S, Pizzolo G, et al.
CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy.
Blood.
1995;85:1-14
62.
Stein H, Foss HD, Durkop H, et al.
CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.
Blood.
2000;96:3681-3695
63.
Suzuki G, Sawa H, Kobayashi Y, et al.
Pertussis toxin-sensitive signal controls the trafficking of thymocytes across the corticomedullary junction in the thymus.
J Immunol.
1999;162:5981-5985
64.
Virbasius JV, Virbasius CA, Scarpulla RC.
Identity of GABP with NRF-2, a multisubunit activator of cytochrome oxidase expression, reveals a cellular role for an ETS domain activator of viral promoters.
Genes Dev.
1993;7:380-392
65.
Virbasius CA, Virbasius JV, Scarpulla RC.
NRF-1, an activator involved in nuclear-mitochondrial interactions, utilizes a new DNA-binding domain conserved in a family of developmental regulators.
Genes Dev.
1993;7:2431-2445
66.
Duckett CS, Gedrich RW, Gilfillan MC, Thompson CB.
Induction of nuclear factor
67.
Jones RH, Jones NC.
Mammalian cAMP-responsive element can activate transcription in yeast and binds a yeast factor(s) that resembles the mammalian transcription factor ANF.
Proc Natl Acad Sci U S A.
1989;86:2176-2180
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  P. Borchmann, J. F. Treml, H. Hansen, C. Gottstein, R. Schnell, O. Staak, H.-f. Zhang, T. Davis, T. Keler, V. Diehl, et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma Blood, November 15, 2003; 102(10): 3737 - 3742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Younes and M. E. Kadin Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy J. Clin. Oncol., September 15, 2003; 21(18): 3526 - 3534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Helbig, K. W. Christopherson II, P. Bhat-Nakshatri, S. Kumar, H. Kishimoto, K. D. Miller, H. E. Broxmeyer, and H. Nakshatri NF-{kappa} B Promotes Breast Cancer Cell Migration and Metastasis by Inducing the Expression of the Chemokine Receptor CXCR4 J. Biol. Chem., June 6, 2003; 278(24): 21631 - 21638. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
